Tech Company Financing Transactions
Arvinas Funding Round
Arvinas closed a $19.3 million Series A funding round on 9/27/2013. Investors included 5AM Ventures, Canaan Partners and Connecticut Innovations.
Transaction Overview
Company Name
Announced On
9/27/2013
Transaction Type
Venture Equity
Amount
$19,250,000
Round
Series A
Investors
5AM Ventures (Lead Investor) (Richard Ulevitch)
Canaan Partners (Lead Investor) (Timothy Shannon)
Proceeds Purpose
The funds will support the development of the company's technology which has primary application in multiple oncology indications and potential in inflammatory, autoimmune and rare diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5 Science Park 395 Winchester Ave.
New Haven, CT 06511
USA
New Haven, CT 06511
USA
Phone
Website
Email Address
Overview
Arvinas is a pharmaceutical company focused on protein degradation approaches to develop novel drugs to treat cancer and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Houston
Chief Financial Officer
Sean Cassidy
Chief Scientific Officer
Ian Taylor
Chief Technical Officer
Andrew Crew
Vice President
Angela Cacace
Vice President
Kimberly Wehger
VP - Bus. Development
Matthew Batters
VP - Bus. Development
Randy Teel
VP - Human Resources
Steve Weiss
VP - Manufacturing
John Grosso
VP - Operations
Marcia Moore
Browse more venture capital transactions:
Prev: 9/27/2013: Shopular venture capital transaction
Next: 9/27/2013: Qstream venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs